Evidence map›Paper›PMID 26686676›Full record

ArticleMetabolic brain disease2016

Study of a fetal brain affected by a severe form of tyrosine hydroxylase deficiency, a rare cause of early parkinsonism.

Alba Tristán-Noguero, Héctor Díez, Cristina Jou, Mercè Pineda, Aida Ormazábal, Aurora Sánchez, Rafael Artuch, Àngels Garcia-Cazorla

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Gene therapy for neurotransmitter-related disorders.Journal of inherited metabolic disease · 2024
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Novel advanced patient-derivedFrontiers in neurology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alba Tristán-NogueroLaboratory of Synaptic Metabolism, Fundació Sant Joan de Déu (FSJD), Barcelona, Spain.
Héctor DíezLaboratory of Synaptic Metabolism, Fundació Sant Joan de Déu (FSJD), Barcelona, Spain.
Cristina JouDepartment of Pathology, Hospital Sant Joan de Déu (HSJD), Barcelona, Spain.
Mercè PinedaDepartment of Neurology, Hospital Sant Joan de Déu (HSJD), Passeig Sant Joan de Déu, 2, Esplugues, 08950,, Barcelona, Spain.
Aida OrmazábalDepartment of Clinical Biochemistry, Hospital Sant Joan de Déu (HSJD), Barcelona, Spain.
Aurora SánchezCIBERER (Biomedical Network Research Centre on Rare Diseases), Instituto de Salud Carlos III, Madrid, Spain.
Rafael ArtuchDepartment of Clinical Biochemistry, Hospital Sant Joan de Déu (HSJD), Barcelona, Spain.
Àngels Garcia-CazorlaLaboratory of Synaptic Metabolism, Fundació Sant Joan de Déu (FSJD), Barcelona, Spain. agarcia@hsjdbcn.org.
Hospital Sant Joan de Déu Barcelona · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine hydroxylase (TH) deficiency is an inborn error of dopamine synthesis. Two clinical phenotypes have been described. The THD "B" phenotype produces a severe encephalopathy of early-onset with sub-optimal L-Dopa response, whereas the "A" phenotype has a better L-Dopa response and outcome. The objective of the study is to describe the expression of key synaptic proteins and neurodevelopmental markers in a fetal brain of THD "B" phenotype. The brain of a 16-week-old miscarried human fetus was dissected in different brain areas and frozen until the analysis. TH gene study revealed the p.R328W/p.T399M mutations, the same mutations that produced a B phenotype in her sister. After protein extraction, western blot analyses were performed to assess protein expression. The results were compared to an age-matched control. We observed a decreased expression in TH and in other dopaminergic proteins, such as VMAT 1 and 2 and dopamine receptors, especially D2DR. GABAergic and glutamatergic proteins such as GABA VT, NMDAR1 and calbindin were also altered. Developmental markers for synapses, axons and dendrites were decreased whereas markers of neuronal volume were preserved. Although this is an isolated case, this brain sample is unique and corresponds to the first reported study of a THD brain. It provides interesting information about the influence of dopamine as a regulator of other neurotransmitter systems, brain development and movement disorders with origin at the embryological state. This study could also contribute to a better understanding of the pathophysiology of THD at early fetal stages.

Indexed as

MutationAbortion, SpontaneousBrainDopamineDystonic DisordersFetusHumansParkinsonian DisordersTyrosine 3-MonooxygenaseVesicular Monoamine Transport ProteinsDopamineSLC18A1 protein, humanSLC18A2 protein, humanTyrosine 3-MonooxygenaseVesicular Monoamine Transport ProteinsHuman fetal brainInfantile parkinsonismNeurodevelopmental markersNeurotransmitter systems markersTyrosine hydroxylase deficiency

Identifiers

PMID26686676
OpenAlexW2299414019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.